All News
Filter News
Found 2,082 articles
-
Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens
10/12/2023
Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo -Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023.
-
Aethlon Receives Clearance From Drug Controller General of India For Potential Phase 1 Trial of its Hemopurifier® in Oncology
10/10/2023
Aethlon Medical, Inc. (Nasdaq: AEMD) today announced that it has received clearance from the Drug Controller General of India (DCGI), the central drug authority in India, to conduct a phase 1 safety, feasibility and dose-finding trial of the company's Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®.
-
Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer
10/9/2023
Lexicon Pharmaceuticals, Inc. announced that Tom Garner is joining the company as senior vice president and chief commercial officer, effective October 9, 2023.
-
Following a Phase III failure and the departure of its CEO, Mirati Therapeutics is rumored to be engaged in acquisition discussions with French pharma giant Sanofi, according to Bloomberg.
-
FDA Action Alert: Amgen, Alnylam and BMS
10/2/2023
The FDA will kick off October with an advisory committee meeting for Amgen’s Lumakras and target action dates for Alnylam’s patisiran and Bristol Myers Squibb’s Opdivo. -
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo
9/22/2023
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer.
-
Phanes Therapeutics Announces the Appointment of Internationally Renowned Oncologist Prof. Shun Lu to its Clinical Advisory Board
9/14/2023
Phanes Therapeutics, Inc. announced that Professor Shun Lu, an internationally renowned oncologist and professor at Shanghai Jiao Tong University Chest Hospital, has joined the Company's Clinical Advisory Board.
-
Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
9/11/2023
Bristol Myers Squibb (NYSE: BMY) today announced six-year results from Part 1 of the Phase 3 CheckMate -227 trial, which continues to demonstrate long-term, durable survival benefits of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to chemotherapy in the first-line treatment of patients with metastatic non-small cell lung cancer.
-
CG Oncology Announces Key Executive Appointments in Commercialization, Medical and Manufacturing Operations
9/5/2023
CG Oncology, Inc. announced the appointment of three new members to its executive leadership team: Ambaw Bellete as President and Chief Operating Officer, Swapnil Bhargava, Ph.D. as Chief Technical Officer, and Vijay Kasturi, M.D. as Chief Medical Officer.
-
Guardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as Companion Diagnostic to ENHERTU® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations
9/5/2023
Guardant Health Receives Regulatory Approval in Japan for Guardant360 ® CDx as Companion Diagnostic to ENHERTU ® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations.
-
NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer
9/5/2023
NANOBIOTIX announced the appointment of Louis Kayitalire, MD, as chief medical officer.
-
Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases
8/31/2023
Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced a drug discovery agreement with Ono Pharmaceutical Co., Ltd. to discover and develop novel antibodies for the treatment of autoimmune diseases.
-
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
8/22/2023
Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) as a monotherapy for the adjuvant treatment of adults and adolescents 12 years of age and older with stage IIB or IIC melanoma who have undergone complete resection, based upon results from the CheckMate -76K trial.
-
Evogene Reports Second Quarter 2023 Financial Results
8/17/2023
Evogene Ltd. today announced its financial results for the second quarter period ended June 30, 2023.
-
Biomica Opens Second Site to Advance Its Immuno-Oncology Drug Trials at Davidoff Center
8/15/2023
Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), has announced the opening of a second site at The Davidoff Cancer Center for its ongoing Phase I clinical trial of its immuno-oncology drug candidate, BMC128.
-
CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results
8/11/2023
CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2023, as well as key clinical and corporate developments.
-
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2023 Financial Results
8/10/2023
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided a business update and reported its financial results for the quarter ended June 30, 2023.
-
Following an FDA approval and a Phase III flop, Mirati CEO David Meek has resigned in a “mutually agreed” decision, the company announced late Tuesday as it searches for a permanent replacement.
-
Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
8/8/2023
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the second quarter 2023 along with recent pipeline and corporate updates.
-
Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update
8/3/2023
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended June 30, 2023 and provided a business update.